
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Yale researchers have announced a breakthrough in safe and effective administration of potential antiretroviral drugs: small interfering RNA, known as siRNA, molecules that silence genes. SiRNAs, the researchers say in an advance online report in the journal Nature Materials, could be first step in the development of a new kind of treatment for sexually transmitted diseases. 'RNA interference is a promising approach for prevention and treatment of human disease,' says lead author Kim Woodrow, a postdoctoral fellow in Yale's school of engineering and applied science. 'We wanted to develop a new strategy of delivering siRNAs with a Food and Drug Administration-approved material.' As their name suggests, siRNAs interfere and knock out the function of genes in higher organisms as well as in microbes that may cause STDs. The researchers designed siRNAs to target a gene expressed widely in the lining of the female mouse reproductive tract, in this proof-of-principle work. Using densely loaded nanoparticles made of a biodegradable polymer known as PLGA, the researchers created a stable 'time release' vehicle for delivery of siRNAs to sensitive mucosal tissue like that of the female reproductive system. They found that the particles, loaded with the drug agent, moved effectively in two important ways, penetrating to reach cells below the surface of the mucosa and distributing throughout the vaginal, cervical, and uterine regions. Furthermore, the siRNAs stayed in the tissues for at least a week and knockdown of gene activity lasted up to 14 days. While past work has focused on delivery of siRNAs with liposomes, bubble-like carriers made of phospholipids similar to those found in cell membranes, liposomes are potentially more toxic to the mucosal tissues and are unable to provide sustained release. In the current work, the researchers demonstrated that PLGA nanoparticles were safer than the best current lipid vehicles. Gene interference therapy is moving rapidly from basic research to application. The PLGA packaging these researchers chose is already approved as safe and nontoxic by the FDA, speeding the path to clinical trials for infectious agents such as HPV and HIV. 'Before human clinical testing can begin, our next step in research will be to test this approach directly in disease models -- for example, in the HIV model mice that have an immune system genetically identical to humans,' says senior author W. Mark Saltzman, the Goizueta Foundation professor of biomedical engineering and chemical engineering. This approach holds promise for global health and the ability of people to self-apply antimicrobial treatments. Woodrow says, 'It is safe and effective and much easier than getting an injection of vaccine.'
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Plus: Featured Video
Latest Stories
7 Uplifting Films To Celebrate Trans Awareness Week & Where To Stream Them
November 17 2023 10:25 AM
Out's Deal Guide: Grab Your 50% Off Amazon Fire Tablets & More Recommended Deals on Amazon Today!
November 03 2023 3:44 PM
Unlock Massive Savings at 'The Holiday Shop': Amazon's Hottest Deals of the Season Await!
November 02 2023 2:17 PM
Dianne Feinstein’s Commitment to People Living With HIV Won’t Be Forgotten
November 02 2023 1:27 PM
PEPFAR in Peril: The Far-Right Wants to End the Lifesaving Global HIV Program
October 24 2023 1:52 PM
Plus Nov/Dec Issue: PEPFAR in Danger & Our Allies and Advocates of the Year
October 23 2023 11:53 AM
Trending stories
Most Recent
Recommended Stories for You
HIV Plus Editors
Editor
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.